$TARA
Protara Therapeutics, Inc.

2015 Q3 Form 10-Q Financial Statement

#000117184315004685 Filed on August 13, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2015 Q2 2014 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.000M $1.890M $910.0K
YoY Change 92.31% 107.69% 33.82%
% of Gross Profit
Research & Development $3.078M $3.090M $1.596M
YoY Change 73.6% 93.61% 83.45%
% of Gross Profit
Depreciation & Amortization $10.00K $10.00K $0.00
YoY Change 0.0% -100.0%
% of Gross Profit
Operating Expenses $5.082M $4.981M $2.508M
YoY Change 80.6% 98.6% 61.81%
Operating Profit -$5.082M -$4.981M -$2.508M
YoY Change -3892.54% 98.6%
Interest Expense $29.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$301.0K -$91.00K -$55.00K
YoY Change -94.34% 65.45%
Pretax Income -$5.380M -$5.070M -$2.560M
YoY Change 3.86% 98.05% 65.16%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.383M -$5.072M -$2.563M
YoY Change 3.9% 97.89% 65.35%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$13.12M -$12.37M -$7.314M
COMMON SHARES
Basic Shares Outstanding 16.46M 240.4K
Diluted Shares Outstanding 240.4K

Balance Sheet

Concept 2015 Q3 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $70.50M $74.70M $25.50M
YoY Change 224.88% 192.94%
Cash & Equivalents $35.98M $16.82M $8.646M
Short-Term Investments $34.60M $57.90M $16.80M
Other Short-Term Assets $800.0K $1.100M $400.0K
YoY Change 300.0% 175.0%
Inventory
Prepaid Expenses $829.0K $1.052M
Receivables
Other Receivables
Total Short-Term Assets $71.38M $75.79M $25.90M
YoY Change 225.92% 192.62%
LONG-TERM ASSETS
Property, Plant & Equipment $221.0K $102.0K $100.0K
YoY Change 121.0% 2.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $686.0K $685.0K $1.200M
YoY Change -68.82% -42.92%
Total Long-Term Assets $907.0K $787.0K $1.200M
YoY Change -60.57% -34.42%
TOTAL ASSETS
Total Short-Term Assets $71.38M $75.79M $25.90M
Total Long-Term Assets $907.0K $787.0K $1.200M
Total Assets $72.28M $76.58M $27.10M
YoY Change 198.69% 182.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $591.0K $502.0K $1.000M
YoY Change -40.9% -49.8%
Accrued Expenses $2.235M $2.202M $2.000M
YoY Change 39.69% 10.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.168M $2.765M $5.900M
YoY Change 17.33% -53.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $84.00K $51.00K $6.600M
YoY Change -99.29% -99.23%
Total Long-Term Liabilities $84.00K $51.00K $6.600M
YoY Change -99.29% -99.23%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.168M $2.765M $5.900M
Total Long-Term Liabilities $84.00K $51.00K $6.600M
Total Liabilities $3.252M $2.816M $12.50M
YoY Change -77.73% -77.47%
SHAREHOLDERS EQUITY
Retained Earnings -$124.9M -$119.5M
YoY Change
Common Stock $16.00K $16.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $69.03M $73.76M $14.60M
YoY Change
Total Liabilities & Shareholders Equity $72.28M $76.58M $27.10M
YoY Change 198.69% 182.56%

Cashflow Statement

Concept 2015 Q3 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income -$5.383M -$5.072M -$2.563M
YoY Change 3.9% 97.89% 65.35%
Depreciation, Depletion And Amortization $10.00K $10.00K $0.00
YoY Change 0.0% -100.0%
Cash From Operating Activities -$3.910M -$4.600M -$2.670M
YoY Change 5.39% 72.28% 66.88%
INVESTING ACTIVITIES
Capital Expenditures -$130.0K -$30.00K -$40.00K
YoY Change 1200.0% -25.0%
Acquisitions
YoY Change
Other Investing Activities $23.19M $11.61M -$16.80M
YoY Change -1480.36% -169.11% -772.0%
Cash From Investing Activities $23.06M $11.57M -$16.84M
YoY Change -1472.62% -168.71% -773.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 40.00K 60.00K 24.56M
YoY Change -500.0% -99.76%
NET CHANGE
Cash From Operating Activities -3.910M -4.600M -2.670M
Cash From Investing Activities 23.06M 11.57M -16.84M
Cash From Financing Activities 40.00K 60.00K 24.56M
Net Change In Cash 19.19M 7.030M 5.050M
YoY Change -455.37% 39.21% 461.11%
FREE CASH FLOW
Cash From Operating Activities -$3.910M -$4.600M -$2.670M
Capital Expenditures -$130.0K -$30.00K -$40.00K
Free Cash Flow -$3.780M -$4.570M -$2.630M
YoY Change 2.16% 73.76% 64.38%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001359931
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
dei Document Type
DocumentType
10-Q
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16458714
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Registrant Name
EntityRegistrantName
PROTEON THERAPEUTICS INC
dei Entity Voluntary Filers
EntityVoluntaryFilers
No
dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
prto Accretion Of Redeemable Convertible Preferred Stock To Redemption Value
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue
prto Accretion Of Redeemable Convertible Preferred Stock To Redemption Value
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue
3409000
prto Change In Fair Value Of Investor Rights And Obligation
ChangeInFairValueOfInvestorRightsAndObligation
prto Change In Fair Value Of Investor Rights And Obligation
ChangeInFairValueOfInvestorRightsAndObligation
-18000
prto Foreign Currency Remeasurement Gain Loss
ForeignCurrencyRemeasurementGainLoss
-6000
prto Foreign Currency Remeasurement Gain Loss
ForeignCurrencyRemeasurementGainLoss
CY2002Q1 prto Royalty Payment Percentage Of Net Sales
RoyaltyPaymentPercentageOfNetSales
0.025
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
502000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
917000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-415000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-6000
CY2015Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2202000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1421000
CY2015Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6000
CY2015Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
193266000
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
192324000
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
476000
CY2014Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
883000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
49000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
742000
CY2015Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1758000
CY2014Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9375000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1758000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9375000
CY2015Q2 us-gaap Assets
Assets
76575000
CY2014Q4 us-gaap Assets
Assets
84798000
CY2015Q2 us-gaap Assets Current
AssetsCurrent
75788000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
84601000
CY2015Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
74027000
CY2014Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
83585000
CY2015Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
57916000
CY2014Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
14761000
CY2015Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
57919000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
14755000
CY2015Q2 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
57919000
CY2014Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
14755000
us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
9000
CY2014 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
-6000
CY2014 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
-6000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68840000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2793000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16817000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8646000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-52023000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5853000
CY2015Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
74700000
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2760284
CY2014Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1947849
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16458477
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16448455
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16458477
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16448455
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
16000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
16000
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5069000
CY2014Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2586000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9643000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5417000
CY2013Q3 us-gaap Convertible Debt
ConvertibleDebt
4300000
CY2013Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.08
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
17000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
13000
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-18.55
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-36.64
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-6000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
CY2013Q3 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
1400000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2338000
CY2015Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
112000
CY2015Q2 us-gaap Loans Pledged As Collateral
LoansPledgedAsCollateral
14000
CY2015Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-126000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-126000
CY2015Q2 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-14000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-14000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-112000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
CY2015Q2 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-112000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1891000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
912000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3878000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1656000
CY2015Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2014Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
366000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1617000
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
81000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
115000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
198000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
1000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
419000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1480000
CY2015Q2 us-gaap Interest Expense
InterestExpense
CY2014Q2 us-gaap Interest Expense
InterestExpense
29000
us-gaap Interest Expense
InterestExpense
us-gaap Interest Expense
InterestExpense
857000
CY2015Q2 us-gaap Investment Income Net
InvestmentIncomeNet
37000
CY2014Q2 us-gaap Investment Income Net
InvestmentIncomeNet
3000
us-gaap Investment Income Net
InvestmentIncomeNet
77000
us-gaap Investment Income Net
InvestmentIncomeNet
3000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
93000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
93000
CY2015Q2 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
14000
CY2014Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
39000
CY2015Q2 us-gaap Liabilities
Liabilities
2816000
CY2014Q4 us-gaap Liabilities
Liabilities
2338000
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
76575000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
84798000
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2765000
CY2014Q4 us-gaap Loans Pledged As Collateral
LoansPledgedAsCollateral
39000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
59000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
24563000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-43606000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-14476000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8470000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4234000
us-gaap Net Income Loss
NetIncomeLoss
-9652000
us-gaap Net Income Loss
NetIncomeLoss
-5394000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-5072000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-2563000
CY2015Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5072000
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4460000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9652000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8803000
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-91000
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-55000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-51000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-953000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
4981000
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
2508000
us-gaap Operating Expenses
OperatingExpenses
9601000
us-gaap Operating Expenses
OperatingExpenses
4441000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4981000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2508000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9601000
us-gaap Operating Income Loss
OperatingIncomeLoss
-4441000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
504000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
84000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
84000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
168000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
168000
CY2015Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
685000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
114000
CY2015Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3000
CY2014Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-23000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-23000
CY2015Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
61000
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
CY2015Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
51000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-128000
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-29000
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-128000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-99000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
437000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
58890000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
16795000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
36000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
36000
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2015Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1052000
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1006000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
52000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
us-gaap Proceeds From Issuance Of Redeemable Preferred Stock
ProceedsFromIssuanceOfRedeemablePreferredStock
us-gaap Proceeds From Issuance Of Redeemable Preferred Stock
ProceedsFromIssuanceOfRedeemablePreferredStock
25000000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
15320000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
2355000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
102000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
83000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3090000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1596000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5723000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2785000
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-119526000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-109874000
us-gaap Royalty Expense
RoyaltyExpense
0
CY2015Q2 us-gaap Security Deposit
SecurityDeposit
14000
us-gaap Share Based Compensation
ShareBasedCompensation
883000
us-gaap Share Based Compensation
ShareBasedCompensation
49000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
751204
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.14
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
526591
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7709000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
19772000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1235526
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1757959
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.19
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.62
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
18802000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1650391
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.48
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.83
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.29
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
11066000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y73D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y36D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y182D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y146D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
4158
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
73759000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
82460000
CY2015Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
CY2014Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1897000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
3409000
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; font-style: italic; font-weight: bold; margin: 0pt">Use of Estimates</div><div style=" font-size: 10pt; margin: 0.2pt 0 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div><div style=" font-size: 10pt; text-indent: 16.65pt; margin: 0pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company&#x2019;s management evaluates its estimates, which include, but are not limited to, estimates related to convertible notes, stock-based compensation expense, clinical trial accruals and reported amounts of revenues and expenses during the reported period. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</div><div style=" font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</div><div style=" font-size: 10pt; text-indent: 16.65pt; margin: 0pt">The Company historically utilized significant estimates and assumptions in determining the fair value of its Common Stock. The Company utilized various valuation methodologies in accordance with the framework of the 2004 and 2013 American Institute of Certified Public Accountants Technical Practice Aids, <div style="display: inline; font-style: italic;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</div>, to estimate the fair value of its Common Stock prior to its IPO. Each valuation methodology included estimates and assumptions that required the Company&#x2019;s judgment.</div><div style=" font-size: 10pt; text-indent: 16.65pt; margin: 0pt">&nbsp;</div><div style=" font-size: 10pt; text-indent: 16.65pt; margin: 0pt">These estimates and assumptions included a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, the prices at which the Company sold shares of Preferred Stock, the superior rights and preferences of securities senior to the Company&#x2019;s Common Stock at the time and the likelihood of achieving a liquidity event, such as an initial public offering or a sale of the Company. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of Common Stock at each valuation date and materially affected the financial statements.</div></div></div></div>
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16449937
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
240374
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16449316
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
240254

Files In Submission

Name View Source Status
0001171843-15-004685-index-headers.html Edgar Link pending
0001171843-15-004685-index.html Edgar Link pending
0001171843-15-004685.txt Edgar Link pending
0001171843-15-004685-xbrl.zip Edgar Link pending
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gff10q_081115.htm Edgar Link pending
prto-20150630.xml Edgar Link completed
prto-20150630.xsd Edgar Link pending
prto-20150630_cal.xml Edgar Link unprocessable
prto-20150630_def.xml Edgar Link unprocessable
prto-20150630_lab.xml Edgar Link unprocessable
prto-20150630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending